Details
Category: Volume 05 Issue 12 December 2017
Hits: 1470

Title: Existence of Burkholderia cepacia at Burn and Intensive Care Units in Alexandria Main University Hospital, Egypt

Authors: Mohamed A. El-Barrawy, Osama N. Mohamed, Abass E. Behery, Walaa A. Hazzah, Asmaa A. Hendawy

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i12.28

Abstract

Nosocomial spread of B. cepacia complex (Bcc) isolates amongst non- cystic fibrosis (CF) patients especially immunocompromised patients has been documented, where inadequate laboratory identification and limited treatment options are considered the main obstacles hindering accurate diagnosis and thus proper therapeutic outcome. The present study aimed to detect the isolation percentage of BCC from patients who admitted to ICUs and burn units of Alexandria Main University Hospital during 6 months from April to October 2015. A total of 150 clinical samples were collected from these patients. All samples were cultured and subjected to microbiological procedures for isolation and identification of isolates. Out of 150 clinical samples cultured, 128(85.3%) showed isolates and 22(14.7%) no growth. The majority of isolates causing burn wound infection were P.aeruginosa (31.0%), followed by B.cepacia (30.0%), E.coli (17.0%) and S.aureus (MRSA) (10.0%). BCC was further identified by the BSCA and PCR system (rec A gene). Antibiotic susceptibility tests revealed that all Bcc isolated were Multi Drug Resistant (MDR), the lowest percentage of BCC resistance was against Imipinem (IPM) and Meropenem (MEM)(50% each).

Abbreviations: Bcc, Burkholderia cepacia complex; CF, cystic fibrosis; ICUs, Intensive care units; MDR, Multi Drug Resistant; NFGNB, nosocomial non-fermentative Gram negative bacilli; BCSA, B. cepacia selective agar.

Keywords: Burkholderia cepacia complex; Identification; Antimicrobial susceptibility.

References

  1. Govan JR, Brown PH, Maddison J. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993;342:15–9.
  2. Pegues DA, Carson LA, Tablan OC. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. J Pediatr 1994;124:694–702.
  3. Gales C, Jones N, Andrade S, Sader S. Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997–2002). Mem Inst Oswaldo Cruz, Rio de Janeiro 2005;100(6):571–8.
  4. Geftic SG, Heymann H, Adair FW. Fourteen year survival of Pseudomonas cepacia in a salts solution preserved with benzalkonium chloride. Appl Environ Microbiol 1979;37(3):505–10.
  5. Johnston RB. Clinical aspects of chronic granulomatous disease. Curr Opin Haematol 2001;8(1):17–22.
  6. Sousa A, Ramos G, Leita˜o H. Burkholderia cepacia complex: emerging multihost pathogens equipped with a wide range of virulence factors and determinants. Int J Microbiol 2010;2011:1–9.
  7. Mukhopadhyay C, Bhargava A, Ayyagari A. Two novel clinical presentations of Burkholderia cepacia infection. J Clin Microbiol 2004;42:3904–5.
  8. Gautam V, Ray P, Puri GD, Sharma K, Vandamme P, Madhup SK, et al. Investigation of Burkholderia cepacia complex in septicaemic patients in a Tertiary Care Hospital, India. Nepal Med Coll J 2009;11(4):222–4.
  9. Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: beyond Pseudomonas and acinetobacter. Indian J Med Microbiol 2011;29:4–12.
  10. LiPuma JJ, Coenye T, Vandamme P, John RW. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001;39(10):3427.
  11. Shelly DB, Spilker T, Gracely EJ, Coenye T, Vandamme P, LiPuma JJ. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J Clin Microbiol 2000;38:3112–5.
  12. Van-Pelt C, Verduin CM, Goessens WH, Vos MC, Tu¨mmler B, Segonds C. Identification of Burkholderia spp in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol 1999;37:2158–64.
  13. Coenye T, Vandamme P. Molecular microbiology and genomics book. first edition. United Kingdom: Taylor & Francis; 2007.
  14. Bevivino A, Dalmastri C, Tabacchioni S, Chiarini L, Belli ML, Piana S, et al. Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J Clin Microbiol 2002;40:846–51.
  15. Vermis K, Vandamme PA, Nelis HJ. Burkholderia cepacia complex genomovars: utilization of carbon sources, susceptibility to antimicrobial agents and growth on selective media. J Appl Microbiol 2003;95:1191–9.
  16. Nzula S, Vandamme P, Govan JR. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. J Antimicrob Chemother 2002;50:265–9.
  17. McDowell A, Mathenthiralingam E, Dodd M, Martin S, etal. PCR based detection ad identification of burkolderia cepacia complex pathogens in sputum from cystic fibrosis patients. J clin Microbiol. 2001; 39(12): 4247-55.
  18. Eram S, Nejad Q, Khatami G, Nafissi N. Detection of Burkholderia cepacia complex in patients with cystic fibrosis. Tanaffos 2004; 3(9): 47–52.
  19. Omer N, Abdel ElRaouf H, Okasha H, Nabil N. Microbiological assessment of Burkholderia cepacia complex (Bcc) isolates in Alexandria Main University Hospital. Alex J Med 2015; 51(1):41-46.
  20. Dizbay M, Tunccan O, Sezer B, Aktas F, Arman D. Nosocomial Burkholderia cepacia infections in a Turkish University Hospital: a five-year surveillance. J Infect Dev Countries 2009;3(4):273–7.
  21. Mabrouk A, Maher A, Nasser S. An epidemiologic study of elderly burn patients in Ain Shams University burn unit, Cairo, Egypt. Burns. 2003;29(7):687-90.
  22. Henry D, Campbell M, McGimpsey C, Clarke A, Louden L, Burns JL, et al. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol 1999;37:1004–7.
  23. Segonds C, Clavel-Batut P, Thouverez M,  Grenet D,  Coustumier A,  Plésiat P et al. Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli.. J Clin Microbiol 2009;47(5):1510–6.
  24. Kiska D, Kerr A, Jones M, Caracciolo J, Eskridge B, Jordan M et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 1996; 34:886–91.
  25. Gautam V, Ray P, Vandamme P, Chatterjee SS, Das A, et al. Identification of lysine positive non fermenting gram negative bacilli (Stenotrophomonas maltophilia and Burkholderia cepacia complex). Indian J Med Microbiol 2009;27(2):128–33.

Corresponding Author

Asmaa A. Hendawy

Department of Microbiology, Faculty of Medicine,

University of Alexandria, Egypt